Clopidogrel Pharmacogenetics-Reference-Cited by-同舟云学术

Clopidogrel Pharmacogenetics

Published:2006-08 Issue:8 Volume:26 Page:1681-1683
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:ATVB

Author:

Beitelshees Amber L.¹,McLeod Howard L.¹

Affiliation:

1. From the Department of Medicine, Cardiovascular Division (A.L.B.), and the Division of Oncology and Departments of Genetics and Molecular Biology and Pharmacology (H.L.M.), Washington University School of Medicine, St. Louis, Mo.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. Clopidogrel for Coronary Stenting

2. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial

3. Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation

4. Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel

5. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome;Annals of Laboratory Medicine;2018-09-28

2. Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system;Pharmacy Practice;2017-06-30

3. New paradigms in GPCR drug discovery;Biochemical Pharmacology;2015-12

4. A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs;Current Pharmaceutical Design;2012-04-23

5. Pharmacogenomics of Cardiovascular Drugs;Pharmacogenomics in Clinical Therapeutics;2012-02-24